首页> 美国卫生研究院文献>Current Urology >The Floppy Iris Syndrome – What Urologists and Ophthalmologists Need to Know
【2h】

The Floppy Iris Syndrome – What Urologists and Ophthalmologists Need to Know

机译:软盘虹膜综合征–泌尿科医师和眼科医师需要了解的知识

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionBenign prostatic hyperplasia (BPH) and cataract formation are common in older people. Medical management of symptomatic BPH is often preferred to surgical treatment as surgery increases the risk of morbidities, whereas, surgery is the main form of treatment to restore sight in patient with cataract. The clinical treatment of BPH is either alpha-1 adrenergic antagonist alone or combination of alpha reductase inhibitor and alpha adrenergic receptor (AR) antagonist. There are four alpha-AR antagonists currently available to treat BPH. The uroselective alpha-blocker tamsulosin is the most commonly used drug among all. Studies showed that the majority of the patients who develop intraoperative floppy iris syndrome (IFIS) were on tamsulosin. Women are more likely to develop cataract than men and some recent studies showed that tamsulosin is effective in treating female lower urinary tract symptoms and thereby can cause IFIS during cataract surgery.
机译:简介良性前列腺增生(BPH)和白内障形成在老年人中很常见。有症状的BPH的医学管理通常比手术治疗更可取,因为手术会增加发病的风险,而手术是恢复白内障患者视力的主要治疗形式。 BPH的临床治疗可以是单独的α-1肾上腺素拮抗剂,也可以是α还原酶抑制剂和α肾上腺素受体(AR)拮抗剂的组合。目前有四种α-AR拮抗剂可用于治疗BPH。尿液选择性α受体阻滞剂坦索罗辛是所有药物中最常用的药物。研究表明,术中出现软性虹膜综合症(IFIS)的大多数患者都使用坦洛新。女性比男性更容易患白内障,最近的一些研究表明坦洛新可以有效治疗女性下尿路症状,从而在白内障手术中引起IFIS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号